SAG and hepatocellular carcinoma: Currently, widespread application of interferon and nucleos(t)ide analogs (NUCs) attains significant improvement in restraining HBV replication, decreasing the rates of hepatocellular carcinoma and hepatic failure in patients with chronic hepatitis B (CHB); however, achieving sAg loss as an optimal endpoint is still burdensome and challenging (2, 3).